Cloud P. Paweletz

22.1k total citations · 7 hit papers
136 papers, 10.8k citations indexed

About

Cloud P. Paweletz is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Cloud P. Paweletz has authored 136 papers receiving a total of 10.8k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Pulmonary and Respiratory Medicine, 57 papers in Molecular Biology and 55 papers in Oncology. Recurrent topics in Cloud P. Paweletz's work include Cancer Genomics and Diagnostics (48 papers), Lung Cancer Treatments and Mutations (44 papers) and Advanced Proteomics Techniques and Applications (23 papers). Cloud P. Paweletz is often cited by papers focused on Cancer Genomics and Diagnostics (48 papers), Lung Cancer Treatments and Mutations (44 papers) and Advanced Proteomics Techniques and Applications (23 papers). Cloud P. Paweletz collaborates with scholars based in United States, Japan and United Kingdom. Cloud P. Paweletz's co-authors include Pasi A. Jänne, Geoffrey R. Oxnard, Lance A. Liotta, Yanan Kuang, Kenneth S. Thress, Emanuel F. Petricoin, Emanuel F. Petricoin, John W. Gillespie, Mireille Cantarini and Ryan S. Alden and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Cloud P. Paweletz

132 papers receiving 10.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

2015 1.2k citations Cloud P. Paweletz, Daniel Stetson et al. profile →
Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front

2001 746 citations Cloud P. Paweletz et al. profile →
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer

2016 641 citations Geoffrey R. Oxnard, Ryan S. Alden et al. profile →
Noninvasive Detection of Response and Resistance in EGFR -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

2014 590 citations Geoffrey R. Oxnard, Cloud P. Paweletz et al. Clinical Cancer Research profile →
Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

2018 513 citations Geoffrey R. Oxnard, Yuebi Hu et al. profile →
Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer

2016 432 citations Adrian G. Sacher, Cloud P. Paweletz et al. profile →
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

2022 269 citations Cloud P. Paweletz et al. profile →

Peers

Countries citing papers authored by Cloud P. Paweletz

Since Specialization

Citations

This map shows the geographic impact of Cloud P. Paweletz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cloud P. Paweletz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cloud P. Paweletz more than expected).

Fields of papers citing papers by Cloud P. Paweletz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cloud P. Paweletz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cloud P. Paweletz. The network helps show where Cloud P. Paweletz may publish in the future.

Co-authorship network of co-authors of Cloud P. Paweletz

This figure shows the co-authorship network connecting the top 25 collaborators of Cloud P. Paweletz. A scholar is included among the top collaborators of Cloud P. Paweletz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cloud P. Paweletz. Cloud P. Paweletz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples 2025 ·Clinical Cancer Research ·Cloud P. Paweletz, Alison M. Urvalek, (unknown), Kavita S. Garg, Aimee Bence Lin, Anna M. Szpurka, Anthony Sireci, Geoffrey R. Oxnard, Pasi A. Jänne	0
2	Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer 2024 ·Clinical Cancer Research ·Shin Saito, (unknown), Hoang C.B. Nguyen, Ann Marie Egloff, (unknown), Patrick H. Lizotte, Cloud P. Paweletz, Douglas R. Adkins, Ravindra Uppaluri	8
3	442 CAIX targeted CAR-T cells exhibited antitumor efficacy on renal cell carcinoma (RCC) patient derived organotypic tumor spheroids (PDOTS) 2023 ·SHILAP Revista de lepidopterología ·Yufei Wang, Alicia Buck, Brandon Piel, (unknown), (unknown), Kun Huang, (unknown), Marion Grimaud, (unknown), Miriam Ficial, Sabina Signoretti, Tran C. Thai, Elena V. Ivanova, Cloud P. Paweletz, Ming-Ru Wu, Jon O. Wee, Toni K. Choueiri, Gordon J. Freeman, David A. Barbie, Wayne A. Marasco	1
4	Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC 2021 ·JCO Precision Oncology ·Michael L. Cheng, Marina S.D. Milan, (unknown), Arrien A. Bertram, (unknown), Biagio Ricciuti, Kenneth L. Kehl, Mark M. Awad, Lynette M. Sholl, Cloud P. Paweletz, Pasi A. Jänne	15
5	Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health 2021 ·JCO Precision Oncology ·P. Mickey Williams, (unknown), Steven P. Lund, Kenneth D. Cole, Hua‐Jun He, Chris Karlovich, Cloud P. Paweletz, Daniel Stetson, Laura M. Yee, Dana E. Connors, Susan M. Keating, Benoit Destenaves, Megan H. Cleveland, Christie J. Lau, J. Carl Barrett, Gary J. Kelloff, Robert McCormack	14
6	Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903) 2020 ·Clinical Cancer Research ·Erin M. Bertino, Ryan D. Gentzler, (unknown), Jill Kolesar, Alona Muzikansky, Eric B. Haura, Zofia Piotrowska, D. Ross Camidge, Thomas E. Stinchcombe, (unknown), Jyoti Malhotra, Liza C. Villaruz, Cloud P. Paweletz, Christie J. Lau, Lynette M. Sholl, Naoko Takebe, Jeffrey A. Moscow, Geoffrey I. Shapiro, Pasi A. Jänne, Geoffrey R. Oxnard	31
7	Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade 2019 ·Proceedings of the National Academy of Sciences ·Mohammad Rashidian, Martin W. LaFleur, (unknown), Anushka Dongre, Yun Zhang, Thao H. Nguyen, (unknown), Amir Reza Aref, Christie J. Lau, Cloud P. Paweletz, Xia Bu, Gordon J. Freeman, M. Inmaculada Barrasa, Robert A. Weinberg, Arlene H. Sharpe, Hidde L. Ploegh	87
8	Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors 2019 ·Clinical Cancer Research ·César Serrano, Alessandro Leal, Yanan Kuang, Jeffrey A. Morgan, Constance M. Barysauskas, Jillian Phallen, (unknown), Adrián Mariño‐Enríquez, Andrew J. Wagner, George D. Demetri, Victor E. Velculescu, Cloud P. Paweletz, Jonathan A. Fletcher, Suzanne George	41
9	Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer 2018 ·Cancer Discovery ·Shunsuke Kitajima, Elena V. Ivanova, Sujuan Guo, Ryohei Yoshida, Marco Campisi, Shriram K. Sundararaman, Shoichiro Tange, Yoichiro Mitsuishi, Tran C. Thai, Sayuri Masuda, Brandon Piel, Lynette M. Sholl, Paul T. Kirschmeier, Cloud P. Paweletz, Hideo Watanabe, Mamiko Yajima, David A. Barbie	348
10	Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies 2018 ·Clinical Cancer Research ·Justin I. Odegaard, John J. Vincent, Stefanie Mortimer, James V. Vowles, Bryan C. Ulrich, Kimberly C. Banks, Stephen R. Fairclough, Oliver A. Zill, Marcin Sikora, Reza Bayat Mokhtari, Diana Abdueva, Rebecca J. Nagy, Christine E. Lee, Lesli A. Kiedrowski, Cloud P. Paweletz, Helmy Eltoukhy, Richard B. Lanman, Darya Chudova, AmirAli Talasaz	283
11	False-Positive Plasma Genotyping Due to Clonal Hematopoiesis 2018 ·Clinical Cancer Research ·Yuebi Hu, Bryan C. Ulrich, Julianna Supplee, Yanan Kuang, Patrick H. Lizotte, Nora Feeney, Nicolas Guibert, Mark M. Awad, Kwok‐Kin Wong, Pasi A. Jänne, Cloud P. Paweletz, Geoffrey R. Oxnard	290
12	Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients 2017 ·Clinical Cancer Research ·Yuebi Hu, Ryan S. Alden, Justin I. Odegaard, Stephen R. Fairclough, (unknown), Jennifer Heng, Nora Feeney, Rebecca J. Nagy, (unknown), Bryan C. Ulrich, (unknown), Richard B. Lanman, Judy E. Garber, Cloud P. Paweletz, Geoffrey R. Oxnard	63
13	Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer 2016 ·Cancer Discovery ·Magda Bahcall, Taebo Sim, Cloud P. Paweletz, Jyoti D. Patel, Ryan S. Alden, Yanan Kuang, Adrian G. Sacher, Nam Doo Kim, Christine Lydon, Mark M. Awad, Michael T. Jaklitsch, Lynette M. Sholl, Pasi A. Jänne, Geoffrey R. Oxnard	114
14	A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial 2016 ·Clinical Cancer Research ·Masahiko Yanagita, Amanda J. Redig, Cloud P. Paweletz, Suzanne E. Dahlberg, Allison O’Connell, Nora Feeney, Myriam Taibi, David Boucher, Geoffrey R. Oxnard, Bruce E. Johnson, Daniel B. Costa, David M. Jackman, Pasi A. Jänne	92
15	Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients 2015 ·Clinical Cancer Research ·Cloud P. Paweletz, Adrian G. Sacher, (unknown), Ryan S. Alden, Allison O’Connell, Stacy L. Mach, Yanan Kuang, Leena Gandhi, Paul T. Kirschmeier, Jessie M. English, Lee P. Lim, Pasi A. Jänne, Geoffrey R. Oxnard	177
16	Intratumoral Heterogeneity in EGFR -Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition 2015 ·Cancer Research ·Margaret Soucheray, Marzia Capelletti, (unknown), Yanan Kuang, Cloud P. Paweletz, (unknown), Eiki Kikuchi, Chunxiao Xu, Tarun B. Patel, Fátima Al‐Shahrour, Julián Carretero, Kwok‐Kin Wong, Pasi A. Jänne, Geoffrey I. Shapiro, Takeshi Shimamura	103
17	Noninvasive Detection of Response and Resistance in EGFR -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA breakdown → 2014 ·Clinical Cancer Research ·Geoffrey R. Oxnard, Cloud P. Paweletz, Yanan Kuang, Stacy L. Mach, Allison O’Connell, Melissa M. Messineo, Jason J. Luke, Mohit Butaney, Paul T. Kirschmeier, David M. Jackman, Pasi A. Jänne	590
18	Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors 2010 ·Science Translational Medicine ·Jannik N. Andersen, Sriram Sathyanarayanan, Alessandra Di Bacco, An Chi, Theresa Zhang, (unknown), Brian Dolinski, Manfred Kraus, Brian S. Roberts, William T. Arthur, (unknown), (unknown), Lixia Li, Igor Feldman, (unknown), A. John Rush, Ronald C. Hendrickson, Peter Blume‐Jensen, Cloud P. Paweletz	134
19	Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma 2008 ·Cancer Research ·Valeria R. Fantin, Andrey Loboda, Cloud P. Paweletz, Ronald C. Hendrickson, Jacqueline W. Pierce, Jennifer A. Roth, Lixia Li, (unknown), Susan Korenchuk, Xiaoli Hou, Elizabeth A. Harrington, Sophia Randolph, John F. Reilly, Christopher Ware, Marshall E. Kadin, Stanley R. Frankel, Victoria M. Richon	138
20	De Novo Biosynthetic Profiling of High Abundance Proteins in Cystic Fibrosis Lung Epithelial Cells 2006 ·Molecular & Cellular Proteomics ·Harvey B. Pollard, Ofer Eidelman, Catherine Jozwik, Wei Huang, Meera Srivastava, (unknown), (unknown), (unknown), Tsuyoshi Todo, Thomas N. Darling, Peter J. Mogayzel, Pamela L. Zeitlin, Jerry Wright, William B. Guggino, (unknown), William J. Driscoll, (unknown), Cloud P. Paweletz, David M. Jacobowitz	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact